122 results on '"Layos-Romero A"'
Search Results
2. 20421. DETERIORO FIN DE DOSIS (DFD) EN EL TRATAMIENTO CON ANTICUERPOS MONOCLONALES CONTRA EL CGRP SUBCUTÁNEOS. UN RETO EN EL TRATAMIENTO DE LA MIGRAÑA
- Author
-
A. Layos Romero, A. Andrés López, F. Cuenca, L. Sánchez Mora, B. Ocaña Mora, and L. Torres López
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2024
- Full Text
- View/download PDF
3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
- Author
-
Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S
- Published
- 2023
- Full Text
- View/download PDF
4. Persistent headache after COVID-19: Pathophysioloy, clinic and treatment
- Author
-
Membrilla, J.A., Caronna, E., Trigo-López, J., González-Martínez, A., Layos-Romero, A., Pozo-Rosich, P., Guerrero-Peral, Á., Gago-Veiga, A.B., Andrés-López, A., and Díaz de Terán, J.
- Published
- 2021
- Full Text
- View/download PDF
5. Influence of the COVID-19 outbreak in people with epilepsy: Analysis of a Spanish population (EPICOVID registry)
- Author
-
Sanchez-Larsen, Alvaro, Gonzalez-Villar, Esther, Díaz-Maroto, Inmaculada, Layos-Romero, Almudena, Martínez-Martín, Álvaro, Alcahut-Rodriguez, Cristian, Grande-Martin, Alberto, and Sopelana-Garay, David
- Published
- 2020
- Full Text
- View/download PDF
6. Low-value care practice in headache: a Spanish mixed methods research study
- Author
-
Patricia Pozo-Rosich, Almudena Layos-Romero, Jimmy Martin-Delgado, Julio Pascual, Cristina Bailón, Ana Tentor, Alejandro Santiago, Emilio Ignacio, Antonio Torrés, and José Joaquín Mira
- Subjects
Care ,Cost ,Do not Do recommendations ,Headache ,Patient safety ,Mixed methods ,Medicine - Abstract
Abstract Background Headache is one of the most prevalent diseases. The Global Burden of Disease Study ranks it as the seventh most common disease overall and the second largest neurological cause of disability in the world. The “Do Not Do” recommendations are a strategy for increasing the quality of care and reducing the cost of care for headache. This study aimed to identify specific low-value practices in headache care, determine their frequency, and estimate the cost overrun that they represent, in order to establish “Do not Do” recommendations specifically for headache by consensus and according to scientific evidence. Methods This was a mixed methods research study that combined qualitative consensus-building techniques, involving a multidisciplinary panel of experts to define the “Do Not Do” recommendations in headache care, and a retrospective observational study with review of a randomized set of patient records from the past 6 months in four hospitals, to quantify the frequency of these “Do Not Do” practices. We calculated the sum of direct costs of medical consultations, medicines, and unnecessary diagnostic tests. Results Seven “Do Not Do” recommendations were established for headache. In total, 3507 medical records were randomly reviewed. Low-value practices had a highly variable occurrence, depending on the hospital and type of headache. Overall, 34.1% of low-value practices were related to treatment, 21% were related to overuse of imaging in consultation, and 19% were related to emergency care. The estimated cost of low-value practices in the four hospitals was 203,520.47 euros per 1000 patients. Conclusions This study identified low-value headache practices that need to be eradicated and provided data on their frequency and cost overruns.
- Published
- 2020
- Full Text
- View/download PDF
7. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
- Author
-
Rha, Sun Young, primary, Oh, Do-Youn, additional, Yañez, Patricio, additional, Bai, Yuxian, additional, Ryu, Min-Hee, additional, Lee, Jeeyun, additional, Rivera, Fernando, additional, Alves, Gustavo Vasconcelos, additional, Garrido, Marcelo, additional, Shiu, Kai-Keen, additional, Fernández, Manuel González, additional, Li, Jin, additional, Lowery, Maeve A, additional, Çil, Timuçin, additional, Cruz, Felipe Melo, additional, Qin, Shukui, additional, Luo, Suxia, additional, Pan, Hongming, additional, Wainberg, Zev A, additional, Yin, Lina, additional, Bordia, Sonal, additional, Bhagia, Pooja, additional, Wyrwicz, Lucjan S, additional, Mendez, Guillermo, additional, O'Connor, Juan Manuel, additional, Yanzi Castilla, Alvaro, additional, Cundom, Juan, additional, Kaen, Diego, additional, Wong, Rachel, additional, Ng, Weng, additional, Aghmesheh, Morteza, additional, Peressoni, Mauricio, additional, Andrade, Carlos, additional, Franke, Fabio, additional, Alves, Gustavo, additional, Cruz, Felipe Jose, additional, Vianna, Karina, additional, Monteiro, Maria Marcela, additional, Raphael, Michael, additional, Berry, Scott, additional, Jang, Raymond, additional, Tan, Ann, additional, Asselah, Jamil, additional, Yanez Weber, Patricio, additional, Mahave, Mauricio, additional, Sanchez, Cesar, additional, Salman, Pamela, additional, Zhang, Xiaochun, additional, Liu, Tianshu, additional, Lin, Xiaoyan, additional, Yang, Jianwei, additional, Li, Wei, additional, Ying, Jieer, additional, Chen, Xi, additional, Zeng, Shan, additional, Qu, Yanli, additional, Yang, Lin, additional, Zhao, Lin, additional, Chen, Ping, additional, Li, Enxiao, additional, Ye, Feng, additional, Lu, Jianwei, additional, Liang, Xinjun, additional, Zhao, Qun, additional, Yin, Xianli, additional, Li, Junhe, additional, Ling, Yang, additional, Lv, Guoqing, additional, Li, Shouguo, additional, Guerrero, Alvaro, additional, Rubiano, Juan, additional, Gonzalez Fernandez, Manuel, additional, Manneh Kopp, Ray, additional, Guzman Ramirez, Adrian, additional, Corrales, Luis, additional, Gonzalez Herrera, Ileana, additional, Melichar, Bohuslav, additional, Buchler, Tomas, additional, Svoboda, Tomas, additional, Obermannova, Radka, additional, Vrana, David, additional, Cvek, Jakub, additional, Pfeiffer, Per, additional, Baeksgaard, Lene, additional, Yilmaz, Mette, additional, Boige, Valerie, additional, Lopez-Trabada, Daniel, additional, Borg, Christophe, additional, Pannier, Diane, additional, Hiret, Sandrine, additional, Di Fiore, Frederic, additional, Metges, Jean-Philippe, additional, Arnold, Dirk, additional, Martens, Uwe, additional, Lordick, Florian, additional, Stein, Alexander, additional, Castro, Hugo, additional, Lopez, Karla, additional, Ramirez, Julio, additional, Aguilar, Mynor, additional, Chivalan, Marco, additional, Chan, Wendy, additional, Cheng, Ashley, additional, Yeo, Winnie, additional, Arkosy, Peter, additional, Csoszi, Tibor, additional, Hitre, Erika, additional, Horvath, Zsolt, additional, Lowery, Maeve, additional, McDermott, Ray, additional, Morris, Patrick, additional, Hubert, Ayala, additional, Brenner, Baruch, additional, Ben-Aharon, Irit, additional, Shacham-Shmueli, Einat, additional, Man, Sofia, additional, Pelles Avraham, Sharon, additional, Brenner, Ronen, additional, Mishaeli, Moshe, additional, Di Bartolomeo, Maria, additional, Fazio, Nicola, additional, Lonardi, Sara, additional, Garufi, Carlo, additional, Satoh, Taroh, additional, Hara, Hiroki, additional, Iwagami, Shiro, additional, Yasui, Hisateru, additional, Tsuda, Masahiro, additional, Shimoyama, Tatsu, additional, Shoji, Hirokazu, additional, Sugimoto, Naotoshi, additional, Shibata, Nobuhiro, additional, Yamaguchi, Kensei, additional, Amagai, Kenji, additional, Choda, Yasuhiro, additional, Esaki, Taito, additional, Yabusaki, Hiroshi, additional, Oshima, Takashi, additional, Tsuji, Akihito, additional, Kawakami, Hisato, additional, Kawazoe, Akihito, additional, Ishido, Kenji, additional, Kadowaki, Shigenori, additional, Martinez Rodriguez, Jorge, additional, Herrera Martinez, Marytere, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Balancan, Paola, additional, Damianovich, Dragan, additional, Castro Oliden, Victor, additional, Grados, Julio, additional, Torres, Cesar, additional, Wyrwicz, Lucjan, additional, Wysocki, Piotr, additional, Hajac, Lukasz, additional, Zolnierek, Jakub, additional, Karaszewska, Boguslawa, additional, Rha, Sun Young, additional, Orlova, Rashida, additional, Tjulandin, Sergey, additional, Fadeeva, Natalia, additional, Makarycheva, Yulia, additional, Nosov, Dmitry, additional, Smagina, Maria, additional, Chan, Sze, additional, Jacobs, Conrad, additional, Kraus, Peter, additional, Landers, Gregory, additional, Robertson, Barbara, additional, Ruff, Paul, additional, Schoeman, Elizabeth, additional, Maurel, Jean-Marc, additional, Diez Garcia, Marc, additional, Jimenez Fonseca, Paula, additional, Gallego Plazas, Javier, additional, Rivera Herrero, Fernando, additional, Miranda Poma, Jesus, additional, Layos Romero, Laura, additional, Fritsch, Ralph, additional, Bastian, Sara, additional, Winterhalder, Ralph, additional, Dosso, Sara De, additional, Kossler, Thibaud, additional, Yeh, Kun-Huei, additional, Yen, Chia-Jui, additional, Chen, Yen-Yang, additional, Lin, Johnson, additional, Bilici, Mehmet, additional, Ozguroglu, Mustafa, additional, Cil, Timucin, additional, Oksuzoglu, Berna, additional, Harputluoglu, Hakan, additional, Karaoglu, Aziz, additional, Hacibekiroglu, Ilhan, additional, Erdogan, Bulent, additional, Yalcin, Suayib, additional, Adamchuk, Hryhoriy, additional, Bondarenko, Igor, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Kryzhanivska, Anna, additional, Leshchenko, Lurii, additional, Ilin, Ievgen, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Voitko, Nataliia, additional, Roy, Rajarshi, additional, Young, Anna-Mary, additional, Medley, Louise, additional, Celano, Paul, additional, Overton, Lindsay, additional, Raj, Moses, additional, Dunne, Richard, additional, Wainberg, Zev, additional, Dayyani, Farshid, additional, Larson, Timothy, additional, and Kochenderfer, Mark, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Quality assurance in specialized headache units in Spain: an observational prospective study
- Author
-
Patricia Pozo-Rosich, Alba Martínez-García, Julio Pascual, Emilio Ignacio, Ángel L. Guerrero-Peral, José Balseiro-Gómez, Jesús Porta-Etessam, Germán Latorre-González, Almudena Layos-Romero, César Lucas, and José J. Mira
- Subjects
Headache ,Indicators ,Quality assurance ,Patient safety ,Medicine - Abstract
Abstract Objective To assess the quality of the therapeutic approach in Specialized Headache Units in Spain. Methods An observational (prospective) study was conducted. Anonymized data of 313 consecutive patients during a defined period of time were analyzed and a comparison of performance in 13 consensual quality indicators between Specialized Headache Units and neurology consultations was calculated. Specialized Units and neurology consultations represented the type of provision that Spaniards receive in hospitals. Results The consensus benchmark standard was reached for 8/13 (61%) indicators. Specialized Headache Units performed better in the indicators, specifically in relation to accessibility, equity, safety, and patient satisfaction. Patients attended in Specialized Headache Units had more complex conditions. Conclusion Although there is variability among Specialized Headache Units, the overall quality was generally better than in traditional neurology consultations in Spain.
- Published
- 2019
- Full Text
- View/download PDF
9. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report
- Author
-
Irene Carrillo, Patricia Pozo-Rosich, Julio Pascual, Sandra Rodríguez-Justo, Dolores Jiménez-Hernández, Almudena Layos-Romero, Cristina Bailón-Santamaría, Antonio Torres, Alba Martínez-García, and Emilio Ignacio
- Subjects
Medicine - Abstract
Background Headache is one of the most prevalent and disabling conditions. Its optimal management requires a coordinated and comprehensive response by health systems, but there is still a wide variability that compromises the quality and safety of the care process.Purpose To establish the basis for designing a care pathway for headache patients through identifying key subpathways in the care process and setting out quality and clinical safety standards that contribute to providing comprehensive, adequate and safe healthcare.Method A qualitative research study based on the consensus conference technique. Eleven professionals from the Spanish National Health System participated, seven of them with clinical experience in headache and four specialists in healthcare management and quality. First, identification of the key subpathways in the care process for headache, barriers/limitations for optimal quality of care, and quality and safety standards applied in each subpathway. Second, two consecutive consensus rounds were carried out to assess the content of the subpathway level descriptors, until the expert agreement was reached. Third, findings were assessed by 17 external healthcare professionals to determine their understanding, adequacy and usefulness.Results Seven key subpathways were identified: (1) primary care, (2) emergency department, (3) neurology department, (4) specialised headache unit, (5) hospitalisation, (6) outpatients and (7) governance and management. Sixty-seventh barriers were identified, the most frequent being related to diagnostic errors (36,1%), resource deficiency (25%), treatment errors (19,4%), lack of health literacy (13,9%) and inadequate communications with care transitions (5,6%). Fifty-nine quality and 31 safety standards were defined. They were related to evaluation (23.3%), patient safety (21.1%), comprehensive care (12.2%), treatment (12.2%), clinical practice guidelines (7.8%), counselling (6.7%), training (4.4%) and patient satisfaction (3.3%).Conclusions This proposal incorporates a set of indicators and standards, which can be used to define a pathway for headache patients and determine the levels of quality.
- Published
- 2020
- Full Text
- View/download PDF
10. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
- Author
-
Romero-Sánchez, Carlos Manuel, Díaz-Maroto, Inmaculada, Fernández-Díaz, Eva, Sánchez-Larsen, Álvaro, Layos-Romero, Almudena, García-García, Jorge, González, Esther, Redondo-Peñas, Inmaculada, Perona-Moratalla, Ana Belén, Del Valle-Pérez, José Antonio, Gracia-Gil, Julia, Rojas-Bartolomé, Laura, Feria-Vilar, Inmaculada, Monteagudo, María, Palao, María, Palazón-García, Elena, Alcahut-Rodríguez, Cristian, Sopelana-Garay, David, Moreno, Yóscar, Ahmad, Javaad, and Segura, Tomás
- Published
- 2020
- Full Text
- View/download PDF
11. Eslicarbazepine acetate for trigeminal neuralgia
- Author
-
A. Sanchez-Larsen, D. Sopelana, A. Layos-Romero, and T. Segura
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2020
- Full Text
- View/download PDF
12. Paraneoplastic opsoclonus-myoclonus syndrome in a patient with oesophageal adenocarcinoma
- Author
-
J.A. Del Valle Pérez, I. Redondo Peñas, A. Layos Romero, and T. Segura
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2020
- Full Text
- View/download PDF
13. Acetato de eslicarbazepina en neuralgia del trigémino
- Author
-
A. Sanchez-Larsen, D. Sopelana, A. Layos-Romero, and T. Segura
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2020
- Full Text
- View/download PDF
14. Síndrome opsoclono-mioclono paraneoplásico en paciente con adenocarcinoma de esófago
- Author
-
J.A. del Valle Pérez, I. Redondo Peñas, A. Layos Romero, and T. Segura
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Published
- 2020
- Full Text
- View/download PDF
15. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
- Author
-
David Garcia-Azorin, Almudena Layos-Romero, Jesús Porta-Etessam, Javier A Membrilla, Edoardo Caronna, Alicia Gonzalez-Martinez, Álvaro Sierra Mencia, Tomás Segura, Nuria Gonzalez-García, Javier Díaz-de-Terán, Victor J Gallardo, Ana Beatriz Gago-Veiga, Alejandro Ballvé, Javier Trigo López, María Sastre-Real, Arnau Llauradó, Ana Cornejo, Íñigo de Lorenzo, Ángel Guerrero-Peral, and Patricia Pozo-Rosich
- Subjects
Male ,Time Factors ,Headache ,COVID-19 ,Humans ,Female ,Neurology (clinical) ,General Medicine ,Middle Aged ,Follow-Up Studies - Abstract
Background Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19. Methods This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up. Results We included 905 patients. Their median age was 51 (IQR 45–65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6–39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5–21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7–18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582–0.737). Conclusion The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.
- Published
- 2022
- Full Text
- View/download PDF
16. Persistent headache after COVID-19: Pathophysioloy, clinic and treatment
- Author
-
J.A. Membrilla, E. Caronna, J. Trigo-López, A. González-Martínez, A. Layos-Romero, P. Pozo-Rosich, Á. Guerrero-Peral, A.B. Gago-Veiga, A. Andrés-López, and J. Díaz de Terán
- Subjects
Long COVID ,Post-COVID ,Headache ,General Earth and Planetary Sciences ,COVID-19 ,Review ,Cefalea ,SARS-COV-2 ,Cefalea diaria persistente de novo ,New daily persistent headache ,COVID persistente ,General Environmental Science - Abstract
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. The acute infection is characterised not only by respiratory symptoms, but also by multiple systemic manifestations, including neurological symptoms. Among these, headache is a frequent complaint. As the pandemic progresses and the population of patients recovering from COVID-19 grows, it is becoming apparent that the headache present in the acute stage of the infection may persist for an indeterminate period, becoming a major problem for the patient and potentially leading to disability. In this review we describe the pathophysiological and clinical aspects of persistent headache after COVID-19 based on the information currently available in the literature and the authors’ clinical experience.
- Published
- 2021
17. International Headache Congress 8–12 September 2021
- Author
-
N. Gonzalez Garcia, I. de Lorenzo, A. Cornejo, Javier A Membrilla, Arnau Llaurado, A. Sierra Mencfa, Alejandro Ballve, Victor José Gallardo, M. Sastre-Real, Patricia Pozo-Rosich, A. B. Gago Veiga, Alicia Gonzalez-Martinez, T. Segura, A.L. Guerrero Peral, J. Trigo Lopez, J. Diaz De Terán Velasco, Jesús Porta-Etessam, D. Garcfa-Azorin, A. Layos-Romero, and Edoardo Caronna
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Medicine ,Neurology (clinical) ,General Medicine ,business ,Virology - Published
- 2021
- Full Text
- View/download PDF
18. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
- Author
-
Caronna, Edoardo, Gallardo, Victor José, Egeo, Gabriella, Vázquez, Manuel Millán, Castellanos, Candela Nieves, Membrilla, Javier A, Vaghi, Gloria, Rodríguez-Montolio, Joana, Fabregat Fabra, Neus, Sánchez-Caballero, Francisco, Jaimes Sánchez, Alex, Muñoz-Vendrell, Albert, Oliveira, Renato, Gárate, Gabriel, González-Osorio, Yésica, Guisado-Alonso, Daniel, Ornello, Raffaele, Thunstedt, Cem, Fernández-Lázaro, Iris, Torres-Ferrús, Marta, Alpuente, Alicia, Torelli, Paola, Aurilia, Cinzia, Pére, Raquel Lamas, Castrillo, Maria José Ruiz, Icco, Roberto De, Sances, Grazia, Broadhurst, Sarah, Ong, Hui Ching, García, Andrea Gómez, Campoy, Sergio, Sanahuja, Jordi, Cabral, Goncalo, Beltrán Blasco, Isabel, Waliszewska-Prosół, Marta, Pereira, Liliana, Layos-Romero, Almudena, Luzeiro, Isabel, Dorado, Laura, Álvarez Escudero, María Rocio, May, Arne, López-Bravo, Alba, Martins, Isabel Pavão, Sundal, Christina, Irimia, Pablo, Lozano Ros, Alberto, Gago-Veiga, Ana Beatriz, Juanes, Fernando Velasco, Ruscheweyh, Ruth, Sacco, Simona, Cuadrado-Godia, Elisa, García-Azorín, David, Pascual, Julio, Gil-Gouveia, Raquel, Huerta-Villanueva, Mariano, Rodriguez-Vico, Jaime, Viguera Romero, Javier, Obach, Victor, Santos-Lasaosa, Sonia, Ghadiri-Sani, Mona, Tassorelli, Cristina, Díaz-de-Terán, Javier, Díaz Insa, Samuel, Oria, Carmen González, Barbanti, Piero, and Pozo-Rosich, Patricia
- Abstract
BackgroundAnti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike and many countries have reimbursement policies, which hinder treatments to those who might respond. This study aimed to investigate clinical factors associated with good and excellent response to anti-CGRP MAbs at 6 months.MethodsEuropean multicentre, prospective, real-world study, including high-frequency episodic or chronic migraine (CM) patients treated since March 2018 with anti-CGRP MAbs. We defined good and excellent responses as ≥50% and ≥75% reduction in monthly headache days (MHD) at 6 months, respectively. Generalised mixed-effect regression models (GLMMs) were used to identify variables independently associated with treatment response.ResultsOf the 5818 included patients, 82.3% were females and the median age was 48.0 (40.0–55.0) years. At baseline, the median of MHD was 20.0 (14.0–28.0) days/months and 72.2% had a diagnosis of CM. At 6 months (n=4963), 56.5% (2804/4963) were good responders and 26.7% (1324/4963) were excellent responders. In the GLMM model, older age (1.08 (95% CI 1.02 to 1.15), p=0.016), the presence of unilateral pain (1.39 (95% CI 1.21 to 1.60), p<0.001), the absence of depression (0.840 (95% CI 0.731 to 0.966), p=0.014), less monthly migraine days (0.923 (95% CI 0.862 to 0.989), p=0.023) and lower Migraine Disability Assessment at baseline (0.874 (95% CI 0.819 to 0.932), p<0.001) were predictors of good response (AUC of 0.648 (95% CI 0.616 to 0.680)). These variables were also significant predictors of excellent response (AUC of 0.691 (95% CI 0.651 to 0.731)). Sex was not significant in the GLMM models.ConclusionsThis is the largest real-world study of migraine patients treated with anti-CGRP MAbs. It provides evidence that higher migraine frequency and greater disability at baseline reduce the likelihood of responding to anti-CGRP MAbs, informing physicians and policy-makers on the need for an earlier treatment in order to offer the best chance of treatment success.
- Published
- 2024
- Full Text
- View/download PDF
19. P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
- Author
-
Santos Vivas, C., primary, Salva, F., additional, Fernández-Rodríguez, C., additional, Alonso Orduña, V., additional, Losa, F., additional, Paez, D., additional, Vidal, J., additional, Salud, A., additional, Ribera Fernández, P., additional, Safont Aguilera, M., additional, Tarazona, N., additional, Hernández-Yagüe, X., additional, Layos Romero, L., additional, Garcia-Carbonero, R., additional, Rivera, F., additional, Álvarez Gallego, R., additional, Bellosillo, B., additional, and Montagut, C., additional
- Published
- 2022
- Full Text
- View/download PDF
20. P-195 A cohort of patients (pt) with HER2-positive (HER2+) advanced gastroesophageal cancer (aGEC) treated at our institution after a decade of tailored targeted therapy
- Author
-
Pous Badia, A., primary, Ferrando Díez, A., additional, Hierro Carbó, C., additional, España Fernández, S., additional, Plaja Salarich, A., additional, Notario Rincon, L., additional, Layos Romero, L., additional, Manzano Mozo, J., additional, Font Pous, A., additional, Linares, J., additional, Álvaro Pardo, M., additional, Calsina Berna, A., additional, Sendrós Madroño, M., additional, Hernandez Marfil, A., additional, Riquelme Olivares, M., additional, López Martos, R., additional, Colan Hernández, J., additional, Garsot Savall, E., additional, Caro Gallarín, M., additional, Barluenga Torres, E., additional, Munné, M., additional, and Bugés Sánchez, C., additional
- Published
- 2022
- Full Text
- View/download PDF
21. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European MigraineHeadache Alliance
- Author
-
Sacco S., Lampl C., Maassen van den Brink A., Caponnetto V., Braschinsky M., Ducros A., Little P., Pozo-Rosich P., Reuter U., Ruiz de la Torre E., Sanchez Del Rio M., Sinclair A. J., Martelletti P., Katsarava Z., Cakciri G., Djamandi P., Grabova S., Halili G., Kruja J., Kuqo A., Naco D., Quka A., Stefanidhi L., Vyshka G., Zekja I., Bruera O., Gomez D., Guitian B., Roma J. C., Chen I. L., Bashirova S., Linkov M., Van Den Abbeele D., Vanderschueren G., Araujo R., Arruda R., Catharino A., Ciriaco J., Dalla Corte A., Dornas R., Felsenfeld B., Fonseca Taufner A., Fragoso Y., Hurtado R., Isoni Martins D., Londero R., Melo L., Mignoni K. S., Sgobbi De Souza P. V., Souza M. N., Osman S., Baltzer V., Pacheco Mosquera L. F., Dubroja I., Hucika Z., Lisak M., Lovrencic-Huzjan A., Lusic I., Mahovic Lakusic D., Mikulenka P., Rehulka P., Amin F. M., Antic S., Fakhril-Din Z., Moeller-Hansen J., Munksgaard S., Nan A. M., Pellesi L., Schytz H., Vides M., Braschinsky K., Krikmann U., Roos C., Cauchie A., Christian L., Guegan-Massardier E., Demarquay G., Gilles G., Mawet J., Kuhn E., Lanteri Minet M., Bustuchina Vlaicu M., Moisset X., Muresan M., Najjar-Ravan M., Giraud P., Simonin S., De Gaalon S., Chakhava G., Demuria M., Gegelashvili G., Kapanadze N., Antonakakis A., Gaul C., Forderreuther S., Huhn J. -I., Ibragimov S., Kamm K., Raffaelli B., Czaniera R., Ruscheweyh R., Gavanozi E., Karagiorgis G., Mavridism T., Ertsey C., Shubham D., Callista Tanowi A. D., Erdana Putra S., Hadi D. W., Kurnia L., Nasrul M., Albanese M., Antonaci F., Asioli G. M., Baschi R., Bentivegna E., Brunelli N., Caratozzolo S., Catarci T., Cherchi A., Corbelli I., Costa A., De Luca C., Doretti A., Favoni V., Ghiotto N., Giamberardino M. A., Giani L., Zanchin G., Govone F., Grillo G., Mampreso E., Negro A., Ornello R., Pasculli M., Pensato U., Prudenzano M. P. A., Quintana S., Rapisarda R., Romoli M., Russo A., Russo M., Spuntarelli V., Tiseo C., Torrente A., Vacca A., Vaula G., Vigano A., Vigneri S., Freimane A., Slosberga E., Zvaune L., Tan H. J., Fenech C., Cobilt-Catana R., De La Garza Neme Y., Martinez M., Proano Narvaez J. V., Rodriguez Herrera A., Vazquez D., Grosu O., Jakupi A., Kristoffersen E. S., Tronvik E., Winsvold B. S., Azhar M., Reyes Alvarez M. T., Vilchez Fernandez L., Dayrit G. D., Czapinska-Ciepiela E. K., Fila M., Gryglas-Dworak A., Couto M., Esperanca P., Ferreira A., Gil-Gouveia R., Goncalves A., Lopes M., Lourenco M., Machado J., Marinho M., Miranda M. A., Palavra F., Parreira E., Pavao Martins I., Pereira L., Pereira Monteiro J. M., Leahu P., Aloman S., Abramova E., Akhmadeeva L., Belopasova A., Bogdanova I., Chernyak M., Epifanova M., Fedorova E., Felbush A., Karpova M., Korobkova D., Korotkova D., Latysheva N., Makeeva T., Mikhalkina K., Osipova V., Roshchina O., Serga A., Serousova O. V., Sidorova Y., Skiba I., Skorobogatykh K., Vashchenko N., Apostolski S., Buder N., Kopitovic A., Mirjana J., Podgorac A., Rakic D., Simic S., Zarko M., Trajkovic J. Z., Beltran-Blasco I., Calabria Gallego M. D., Diaz Insa S., Ezpeleta D., Fernandez M., Garcia-Azorin D., Gonzalez-Garcia N., Guerrero A. L., Guillamon E., Herreros Rodriguez J., Layos-Romero A., Medrano V., Minguez-Olaondo A., Navarro Munoz S., Pare Curell M., Ruibal M., Sanchez Alvarez J. M., Santos S., Soler R., Viguera J., Zabalza R., Abdelrahman T., Abobaker Hamza S. B., Mustafa M. N., Edvinsson L., Gantenbein A., Maraffi I., Couturier E., Dirkx T., Hoebert M., Van Oosterhout W., Wim M., Zwartbol R., Bakir M., Demirel H., Erdemoglu A. K., Ertem D. H., Gonullu S., Ilgaz Aydinlar E., Inan L. E., Olmez B., Ozbenli T., Ozge A., Uluduz D., Uyar Cankay T., Yalinay Dikmen P., Saxena A. B., Bozhenko M., Bozhenko N., Bubnov R., Tsurkalenko O., Abu-Arafeh I., Idrovo L., Miller S., Nirmalananthan N., Sinclair A., Taleti E., Valori A., Whitehouse W., Zermansky A., Thura M., Institut Català de la Salut, [Sacco S, Caponnetto V] Neuroscience section – Department of Biotechnological and Applied Clinical Sciences and (Edificio Coppito 2), University of L’Aquila, Via Vetoio, 67100 L’Aquila, Italy. Regional Referral Headache Center of the Abruzzo Region, ASL Avezzano-Sulmona-L’Aquila, L’Aquila, Italy. [Lampl C] Department of Neurology, Headache Medical Centre Linz, Hospital Barmherzige Brüder, Centre of Integrative Medicine (ZiAM) Ordensklinikum Linz, Linz, Austria. [Maassen van den Brink A] Division of Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. [Braschinsky M] Headache Clinic, Department of Neurology, Tartu University Clinics, Tartu, Estonia. [Ducros A] Headache Unit, Neurology Department, Montpellier University Hospital and Montpellier University, Montpellier, France. [Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup d'Investigació en Cefalees i Dolors Neurològics, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Sacco, S., Lampl, C., Maassen van den Brink, A., Caponnetto, V., Braschinsky, M., Ducros, A., Little, P., Pozo-Rosich, P., Reuter, U., Ruiz de la Torre, E., Sanchez Del Rio, M., Sinclair, A. J., Martelletti, P., Katsarava, Z., Cakciri, G., Djamandi, P., Grabova, S., Halili, G., Kruja, J., Kuqo, A., Naco, D., Quka, A., Stefanidhi, L., Vyshka, G., Zekja, I., Bruera, O., Gomez, D., Guitian, B., Roma, J. C., Chen, I. L., Bashirova, S., Linkov, M., Van Den Abbeele, D., Vanderschueren, G., Araujo, R., Arruda, R., Catharino, A., Ciriaco, J., Dalla Corte, A., Dornas, R., Felsenfeld, B., Fonseca Taufner, A., Fragoso, Y., Hurtado, R., Isoni Martins, D., Londero, R., Melo, L., Mignoni, K. S., Sgobbi De Souza, P. V., Souza, M. N., Osman, S., Baltzer, V., Pacheco Mosquera, L. F., Dubroja, I., Hucika, Z., Lisak, M., Lovrencic-Huzjan, A., Lusic, I., Mahovic Lakusic, D., Mikulenka, P., Rehulka, P., Amin, F. M., Antic, S., Fakhril-Din, Z., Moeller-Hansen, J., Munksgaard, S., Nan, A. M., Pellesi, L., Schytz, H., Vides, M., Braschinsky, K., Krikmann, U., Roos, C., Cauchie, A., Christian, L., Guegan-Massardier, E., Demarquay, G., Gilles, G., Mawet, J., Kuhn, E., Lanteri Minet, M., Bustuchina Vlaicu, M., Moisset, X., Muresan, M., Najjar-Ravan, M., Giraud, P., Simonin, S., De Gaalon, S., Chakhava, G., Demuria, M., Gegelashvili, G., Kapanadze, N., Antonakakis, A., Gaul, C., Forderreuther, S., Huhn, J. -I., Ibragimov, S., Kamm, K., Raffaelli, B., Czaniera, R., Ruscheweyh, R., Gavanozi, E., Karagiorgis, G., Mavridism, T., Ertsey, C., Shubham, D., Callista Tanowi, A. D., Erdana Putra, S., Hadi, D. W., Kurnia, L., Nasrul, M., Albanese, M., Antonaci, F., Asioli, G. M., Baschi, R., Bentivegna, E., Brunelli, N., Caratozzolo, S., Catarci, T., Cherchi, A., Corbelli, I., Costa, A., De Luca, C., Doretti, A., Favoni, V., Ghiotto, N., Giamberardino, M. A., Giani, L., Zanchin, G., Govone, F., Grillo, G., Mampreso, E., Negro, A., Ornello, R., Pasculli, M., Pensato, U., Prudenzano, M. P. A., Quintana, S., Rapisarda, R., Romoli, M., Russo, A., Russo, M., Spuntarelli, V., Tiseo, C., Torrente, A., Vacca, A., Vaula, G., Vigano, A., Vigneri, S., Freimane, A., Slosberga, E., Zvaune, L., Tan, H. J., Fenech, C., Cobilt-Catana, R., De La Garza Neme, Y., Martinez, M., Proano Narvaez, J. V., Rodriguez Herrera, A., Vazquez, D., Grosu, O., Jakupi, A., Kristoffersen, E. S., Tronvik, E., Winsvold, B. S., Azhar, M., Reyes Alvarez, M. T., Vilchez Fernandez, L., Dayrit, G. D., Czapinska-Ciepiela, E. K., Fila, M., Gryglas-Dworak, A., Couto, M., Esperanca, P., Ferreira, A., Gil-Gouveia, R., Goncalves, A., Lopes, M., Lourenco, M., Machado, J., Marinho, M., Miranda, M. A., Palavra, F., Parreira, E., Pavao Martins, I., Pereira, L., Pereira Monteiro, J. M., Leahu, P., Aloman, S., Abramova, E., Akhmadeeva, L., Belopasova, A., Bogdanova, I., Chernyak, M., Epifanova, M., Fedorova, E., Felbush, A., Karpova, M., Korobkova, D., Korotkova, D., Latysheva, N., Makeeva, T., Mikhalkina, K., Osipova, V., Roshchina, O., Serga, A., Serousova, O. V., Sidorova, Y., Skiba, I., Skorobogatykh, K., Vashchenko, N., Apostolski, S., Buder, N., Kopitovic, A., Mirjana, J., Podgorac, A., Rakic, D., Simic, S., Zarko, M., Trajkovic, J. Z., Beltran-Blasco, I., Calabria Gallego, M. D., Diaz Insa, S., Ezpeleta, D., Fernandez, M., Garcia-Azorin, D., Gonzalez-Garcia, N., Guerrero, A. L., Guillamon, E., Herreros Rodriguez, J., Layos-Romero, A., Medrano, V., Minguez-Olaondo, A., Navarro Munoz, S., Pare Curell, M., Ruibal, M., Sanchez Alvarez, J. M., Santos, S., Soler, R., Viguera, J., Zabalza, R., Abdelrahman, T., Abobaker Hamza, S. B., Mustafa, M. N., Edvinsson, L., Gantenbein, A., Maraffi, I., Couturier, E., Dirkx, T., Hoebert, M., Van Oosterhout, W., Wim, M., Zwartbol, R., Bakir, M., Demirel, H., Erdemoglu, A. K., Ertem, D. H., Gonullu, S., Ilgaz Aydinlar, E., Inan, L. E., Olmez, B., Ozbenli, T., Ozge, A., Uluduz, D., Uyar Cankay, T., Yalinay Dikmen, P., Saxena, A. B., Bozhenko, M., Bozhenko, N., Bubnov, R., Tsurkalenko, O., Abu-Arafeh, I., Idrovo, L., Miller, S., Nirmalananthan, N., Sinclair, A., Taleti, E., Valori, A., Whitehouse, W., Zermansky, A., Thura, M., and Internal Medicine
- Subjects
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,medicine.medical_specialty ,Pediatrics ,Neurology ,Consensus ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES] ,migraine ,migraine care ,refractory migraine ,resistant migraine ,consensus ,cross-sectional studies ,headache ,humans ,surveys and questionnaires ,migraine disorders ,Pain medicine ,Moderate confidence ,Migraine Disorders ,Medizin ,Consensu ,Migranya - Tractament ,Qüestionaris ,Refractory ,Surveys and Questionnaires ,medicine ,Surveys and Questionnaire ,Humans ,Clinical significance ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders [DISEASES] ,Otros calificadores::/terapia [Otros calificadores] ,Migraine ,Cross-Sectional Studie ,business.industry ,Headache ,técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,General Medicine ,Other subheadings::/therapy [Other subheadings] ,medicine.disease ,Refractory migraine ,Anesthesiology and Pain Medicine ,Cross-Sectional Studies ,Burden ,Medicine ,Neurology (clinical) ,Level of care ,business ,Resistant migraine ,Migraine care ,Human ,Research Article - Abstract
Background New treatments are currently offering new opportunities and challenges in clinical management and research in the migraine field. There is the need of homogenous criteria to identify candidates for treatment escalation as well as of reliable criteria to identify refractoriness to treatment. To overcome those issues, the European Headache Federation (EHF) issued a Consensus document to propose criteria to approach difficult-to-treat migraine patients in a standardized way. The Consensus proposed well-defined criteria for resistant migraine (i.e., patients who do not respond to some treatment but who have residual therapeutic opportunities) and refractory migraine (i.e., patients who still have debilitating migraine despite maximal treatment efforts). The aim of this study was to better understand the perceived impact of resistant and refractory migraine and the attitude of physicians involved in migraine care toward those conditions. Methods We conducted a web-questionnaire-based cross-sectional international study involving physicians with interest in headache care. Results There were 277 questionnaires available for analysis. A relevant proportion of participants reported that patients with resistant and refractory migraine were frequently seen in their clinical practice (49.5% for resistant and 28.9% for refractory migraine); percentages were higher when considering only those working in specialized headache centers (75% and 46% respectively). However, many physicians reported low or moderate confidence in managing resistant (8.1% and 43.3%, respectively) and refractory (20.7% and 48.4%, respectively) migraine patients; confidence in treating resistant and refractory migraine patients was different according to the level of care and to the number of patients visited per week. Patients with resistant and refractory migraine were infrequently referred to more specialized centers (12% and 19%, respectively); also in this case, figures were different according to the level of care. Conclusions This report highlights the clinical relevance of difficult-to-treat migraine and the presence of unmet needs in this field. There is the need of more evidence regarding the management of those patients and clear guidance referring to the organization of care and available opportunities.
- Published
- 2021
- Full Text
- View/download PDF
22. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
- Author
-
Garcia-Azorin, David, primary, Layos-Romero, Almudena, additional, Porta-Etessam, Jesús, additional, Membrilla, Javier A, additional, Caronna, Edoardo, additional, Gonzalez-Martinez, Alicia, additional, Mencia, Álvaro Sierra, additional, Segura, Tomás, additional, Gonzalez-García, Nuria, additional, Díaz-de-Terán, Javier, additional, Gallardo, Victor J, additional, Gago-Veiga, Ana Beatriz, additional, Ballvé, Alejandro, additional, Trigo López, Javier, additional, Sastre-Real, María, additional, Llauradó, Arnau, additional, Cornejo, Ana, additional, de Lorenzo, Íñigo, additional, Guerrero-Peral, Ángel, additional, and Pozo-Rosich, Patricia, additional
- Published
- 2022
- Full Text
- View/download PDF
23. sj-pdf-2-cep-10.1177_03331024211068074 - Supplemental material for Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
- Author
-
Garcia-Azorin, David, Layos-Romero, Almudena, Porta-Etessam, Jes��s, Membrilla, Javier A, Caronna, Edoardo, Gonzalez-Martinez, Alicia, Mencia, ��lvaro Sierra, Segura, Tom��s, Gonzalez-Garc��a, Nuria, D��az-de-Ter��n, Javier, Gallardo, Victor J, Gago-Veiga, Ana Beatriz, Ballv��, Alejandro, Trigo L��pez, Javier, Sastre-Real, Mar��a, Llaurad��, Arnau, Cornejo, Ana, de Lorenzo, ����igo, Guerrero-Peral, ��ngel, and Pozo-Rosich, Patricia
- Subjects
FOS: Psychology ,FOS: Clinical medicine ,170199 Psychology not elsewhere classified ,110319 Psychiatry (incl. Psychotherapy) ,110306 Endocrinology ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,110904 Neurology and Neuromuscular Diseases ,Neuroscience - Abstract
Supplemental material, sj-pdf-2-cep-10.1177_03331024211068074 for Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients by David Garcia-Azorin, Almudena Layos-Romero, Jes��s Porta-Etessam, Javier A Membrilla, Edoardo Caronna, Alicia Gonzalez-Martinez, ��lvaro Sierra Mencia, Tom��s Segura, Nuria Gonzalez-Garc��a, Javier D��az-de-Ter��n, Victor J Gallardo, Ana Beatriz Gago-Veiga, Alejandro Ballv��, Javier Trigo L��pez, Mar��a Sastre-Real, Arnau Llaurad��, Ana Cornejo, ����igo de Lorenzo, ��ngel Guerrero-Peral and Patricia Pozo-Rosich in Cephalalgia
- Published
- 2022
- Full Text
- View/download PDF
24. sj-pdf-1-cep-10.1177_03331024211068074 - Supplemental material for Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
- Author
-
Garcia-Azorin, David, Layos-Romero, Almudena, Porta-Etessam, Jes��s, Membrilla, Javier A, Caronna, Edoardo, Gonzalez-Martinez, Alicia, Mencia, ��lvaro Sierra, Segura, Tom��s, Gonzalez-Garc��a, Nuria, D��az-de-Ter��n, Javier, Gallardo, Victor J, Gago-Veiga, Ana Beatriz, Ballv��, Alejandro, Trigo L��pez, Javier, Sastre-Real, Mar��a, Llaurad��, Arnau, Cornejo, Ana, de Lorenzo, ����igo, Guerrero-Peral, ��ngel, and Pozo-Rosich, Patricia
- Subjects
FOS: Psychology ,FOS: Clinical medicine ,170199 Psychology not elsewhere classified ,110319 Psychiatry (incl. Psychotherapy) ,110306 Endocrinology ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,110904 Neurology and Neuromuscular Diseases ,Neuroscience - Abstract
Supplemental material, sj-pdf-1-cep-10.1177_03331024211068074 for Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients by David Garcia-Azorin, Almudena Layos-Romero, Jes��s Porta-Etessam, Javier A Membrilla, Edoardo Caronna, Alicia Gonzalez-Martinez, ��lvaro Sierra Mencia, Tom��s Segura, Nuria Gonzalez-Garc��a, Javier D��az-de-Ter��n, Victor J Gallardo, Ana Beatriz Gago-Veiga, Alejandro Ballv��, Javier Trigo L��pez, Mar��a Sastre-Real, Arnau Llaurad��, Ana Cornejo, ����igo de Lorenzo, ��ngel Guerrero-Peral and Patricia Pozo-Rosich in Cephalalgia
- Published
- 2022
- Full Text
- View/download PDF
25. Erenumab for the treatment of chronic resistant migraine
- Author
-
Layos-Romero, Almudena, primary, López, Alberto Andrés, additional, and Rojas Bartolomé, Laura, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Erenumab for the treatment of chronic resistant migraine
- Author
-
Almudena, Layos-Romero, Alberto, Andrés López, and Laura, Rojas Bartolomé
- Subjects
Migraine Disorders ,Humans ,Antibodies, Monoclonal, Humanized - Published
- 2022
- Full Text
- View/download PDF
27. Erenumab para el tratamiento de migraña crónica farmacorresistente
- Author
-
Alberto Andrés López, Laura Rojas Bartolomé, and Almudena Layos-Romero
- Subjects
medicine.medical_specialty ,Text mining ,Migraine ,business.industry ,Internal medicine ,MEDLINE ,medicine ,General Medicine ,business ,medicine.disease - Published
- 2022
- Full Text
- View/download PDF
28. 478P TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
- Author
-
Santos, C., primary, Lawrence, P., additional, Lopez-Doriga, A., additional, Ragulan, C., additional, Fontana, E., additional, Desai, K., additional, Ps, H., additional, Elez Fernandez, M.E., additional, Aranda Aguilar, E., additional, Losa, F., additional, Paez, D., additional, Layos Romero, L., additional, Sanjuan, X., additional, Cañas, M.A., additional, Azuara, D., additional, Queralt, B., additional, Fernandez-Calotti, P., additional, Salazar, R., additional, and Sadanandam, A., additional
- Published
- 2021
- Full Text
- View/download PDF
29. P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
- Author
-
C. Santos Vivas, F. Salva, C. Fernández-Rodríguez, V. Alonso Orduña, F. Losa, D. Paez, J. Vidal, A. Salud, P. Ribera Fernández, M. Safont Aguilera, N. Tarazona, X. Hernández-Yagüe, L. Layos Romero, R. Garcia-Carbonero, F. Rivera, R. Álvarez Gallego, B. Bellosillo, and C. Montagut
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
30. P-195 A cohort of patients (pt) with HER2-positive (HER2+) advanced gastroesophageal cancer (aGEC) treated at our institution after a decade of tailored targeted therapy
- Author
-
A. Pous Badia, A. Ferrando Díez, C. Hierro Carbó, S. España Fernández, A. Plaja Salarich, L. Notario Rincon, L. Layos Romero, J. Manzano Mozo, A. Font Pous, J. Linares, M. Álvaro Pardo, A. Calsina Berna, M. Sendrós Madroño, A. Hernandez Marfil, M. Riquelme Olivares, R. López Martos, J. Colan Hernández, E. Garsot Savall, M. Caro Gallarín, E. Barluenga Torres, M. Munné, and C. Bugés Sánchez
- Subjects
Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
31. Erenumab para el tratamiento de migraña crónica farmacorresistente
- Author
-
Layos-Romero, Almudena, primary, Andrés López, Alberto, additional, and Rojas Bartolomé, Laura, additional
- Published
- 2021
- Full Text
- View/download PDF
32. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
- Author
-
José Antonio Del Valle-Pérez, I. Díaz-Maroto, Javaad Ahmad, Ana Belén Perona-Moratalla, María Palao, Álvaro Sánchez-Larsen, Almudena Layos-Romero, Yóscar Moreno, Elena Palazón-García, Jorge García-García, Inmaculada Redondo-Peñas, J. Gracia-Gil, Laura Rojas-Bartolomé, C.M. Romero-Sánchez, Inmaculada Feria-Vilar, David Sopelana-Garay, María Monteagudo, Eva Fernández-Díaz, Tomás Segura, Cristian Alcahut-Rodriguez, and Esther G. González
- Subjects
0301 basic medicine ,Male ,Pediatrics ,medicine.medical_specialty ,Movement disorders ,Pneumonia, Viral ,Anosmia ,Comorbidity ,Article ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,medicine ,Humans ,Optic neuritis ,Registries ,Pandemics ,Cause of death ,Aged ,business.industry ,SARS-CoV-2 ,Dysautonomia ,COVID-19 ,medicine.disease ,Dysgeusia ,030104 developmental biology ,Spain ,Female ,Neurology (clinical) ,medicine.symptom ,Nervous System Diseases ,business ,Coronavirus Infections ,030217 neurology & neurosurgery ,Encephalitis - Abstract
ObjectiveThe coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019. Neurologic symptoms have been reported as part of the clinical spectrum of the disease. We aimed to determine whether neurologic manifestations are common in hospitalized patients with COVID-19 and to describe their main characteristics.MethodsWe systematically reviewed all patients diagnosed with COVID-19 admitted to the hospital in a Spanish population during March 2020. Demographic characteristics, systemic and neurologic clinical manifestations, and complementary tests were analyzed.ResultsOf 841 patients hospitalized with COVID-19 (mean age 66.4 years, 56.2% men), 57.4% developed some form of neurologic symptom. Nonspecific symptoms such as myalgias (17.2%), headache (14.1%), and dizziness (6.1%) were present mostly in the early stages of infection. Anosmia (4.9%) and dysgeusia (6.2%) tended to occur early (60% as the first clinical manifestation) and were more frequent in less severe cases. Disorders of consciousness occurred commonly (19.6%), mostly in older patients and in severe and advanced COVID-19 stages. Myopathy (3.1%), dysautonomia (2.5%), cerebrovascular diseases (1.7%), seizures (0.7%), movement disorders (0.7%), encephalitis (n = 1), Guillain-Barré syndrome (n = 1), and optic neuritis (n = 1) were also reported, but less frequent. Neurologic complications were the main cause of death in 4.1% of all deceased study participants.ConclusionsNeurologic manifestations are common in hospitalized patients with COVID-19. In our series, more than half of patients presented some form of neurologic symptom. Clinicians need to maintain close neurologic surveillance for prompt recognition of these complications. The mechanisms and consequences of severe acute respiratory syndrome coronavirus type 2 neurologic involvement require further studies.
- Published
- 2020
33. Low-value care practice in headache: a Spanish mixed methods research study
- Author
-
Pozo-Rosich, Patricia, Layos-Romero, Almudena, Martin-Delgado, Jimmy, Pascual Gómez, Julio, Bailón-Santamaría, Cristina, Tentor, Ana, Santiago, Alejandro, Ignacio, Emilio, Torrés, Antonio, Mira, José Joaquín, Universitat Autònoma de Barcelona, Enfermería y Fisioterapia, and Universidad de Cantabria
- Subjects
Adult ,Male ,medicine.medical_specialty ,Mixed methods ,Cost ,lcsh:Medicine ,Care ,Drug Costs ,Scientific evidence ,Cost overrun ,03 medical and health sciences ,Indirect costs ,Patient safety ,Random Allocation ,0302 clinical medicine ,Cost of Illness ,Multidisciplinary approach ,Medicine ,Humans ,030212 general & internal medicine ,Retrospective Studies ,business.industry ,Multimethodology ,Medical record ,Do not Do recommendations ,lcsh:R ,Headache ,Retrospective cohort study ,General Medicine ,Anesthesiology and Pain Medicine ,Family medicine ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Research Article - Abstract
Background Headache is one of the most prevalent diseases. The Global Burden of Disease Study ranks it as the seventh most common disease overall and the second largest neurological cause of disability in the world. The “Do Not Do” recommendations are a strategy for increasing the quality of care and reducing the cost of care for headache. This study aimed to identify specific low-value practices in headache care, determine their frequency, and estimate the cost overrun that they represent, in order to establish “Do not Do” recommendations specifically for headache by consensus and according to scientific evidence. Methods This was a mixed methods research study that combined qualitative consensus-building techniques, involving a multidisciplinary panel of experts to define the “Do Not Do” recommendations in headache care, and a retrospective observational study with review of a randomized set of patient records from the past 6 months in four hospitals, to quantify the frequency of these “Do Not Do” practices. We calculated the sum of direct costs of medical consultations, medicines, and unnecessary diagnostic tests. Results Seven “Do Not Do” recommendations were established for headache. In total, 3507 medical records were randomly reviewed. Low-value practices had a highly variable occurrence, depending on the hospital and type of headache. Overall, 34.1% of low-value practices were related to treatment, 21% were related to overuse of imaging in consultation, and 19% were related to emergency care. The estimated cost of low-value practices in the four hospitals was 203,520.47 euros per 1000 patients. Conclusions This study identified low-value headache practices that need to be eradicated and provided data on their frequency and cost overruns.
- Published
- 2020
34. Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report
- Author
-
Montserrat Carreres-Prieto, David López-Sisamón, and Laura Layos-Romero
- Subjects
Pharmacy and materia medica ,RS1-441 ,Therapeutics. Pharmacology ,RM1-950 - Published
- 2015
- Full Text
- View/download PDF
35. Paraneoplastic opsoclonus-myoclonus syndrome in a patient with oesophageal adenocarcinoma
- Author
-
Del Valle Pérez, J.A., primary, Redondo Peñas, I., additional, Layos Romero, A., additional, and Segura, T., additional
- Published
- 2020
- Full Text
- View/download PDF
36. Eslicarbazepine acetate for trigeminal neuralgia
- Author
-
Sanchez-Larsen, A., primary, Sopelana, D., additional, Layos-Romero, A., additional, and Segura, T., additional
- Published
- 2020
- Full Text
- View/download PDF
37. Síndrome opsoclono-mioclono paraneoplásico en paciente con adenocarcinoma de esófago
- Author
-
del Valle Pérez, J.A., primary, Redondo Peñas, I., additional, Layos Romero, A., additional, and Segura, T., additional
- Published
- 2020
- Full Text
- View/download PDF
38. Acetato de eslicarbazepina en neuralgia del trigémino
- Author
-
Sanchez-Larsen, A., primary, Sopelana, D., additional, Layos-Romero, A., additional, and Segura, T., additional
- Published
- 2020
- Full Text
- View/download PDF
39. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report
- Author
-
Pascual, Julio, primary, Pozo-Rosich, Patricia, additional, Carrillo, Irene, additional, Rodríguez-Justo, Sandra, additional, Jiménez-Hernández, Dolores, additional, Layos-Romero, Almudena, additional, Bailón-Santamaría, Cristina, additional, Torres, Antonio, additional, Martínez-García, Alba, additional, Ignacio, Emilio, additional, and Mira, José Joaquín, additional
- Published
- 2020
- Full Text
- View/download PDF
40. ICO-ICS Praxi per al tractament mèdic i amb irradiació de l'adenocarcinoma de pàncrees
- Author
-
Arribas Garcia, Lorena, Berenguer Frances, Miguel Angel, Calvo-Campos, Mariona, Canals-Subirats, Eugeni, Caro-Gallarín, Mònica, Carreras Soler, Maria Josep, Carrizo-Ibarra, Maria V., Garcia Velasco, Adelaida, Gasol Cudos, Ariadna, Guerra-Prió, Silvia, Laquente, Berta, Layos-Romero, Laura, Lezcano-Rubio, Clara, Macarulla Mercadé, Teresa, Navalpotro, Begoña, Peiró, Inmaculada, Sánchez-López, Cristina, Serra-Solé, Òlbia, Gilabert-Sotoca, Marta, Verdaguer Mata, Helena, Burgos Peláez, Rosa, [Arribas-Hortigüela L, Peiró-Martínez I] Unitat Funcional de Nutrició Clínica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Berenguer-Francès MA] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Burgos R] Unitat de Suport Nutricional, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d'Hebron Institut de Recerca, Generalitat de Catalunya, Barcelona, Spain. [Calvo-Campos M, Sánchez-López C, Serra-Solé O] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Canals-Subirats E] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Caro-Gallarín M] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Carreras-Soler MJ] Servei de Farmàcia, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d'Hebron Institut de Recerca, Generalitat de Catalunya, Barcelona, Spain. [Carrizo-Ibarra MV] Servei d’Oncologia Radioteràpica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [García-Velasco A] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. Universitat de Girona, Girona, Spain. Universidad Complutense de Madrid, Madrid, Spain. [Gasol-Cudos A] Servei d’Oncologia Mèdica, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. Universitat de Lleida, Lleida, Spain. [Guerra-Prió S] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Girona, Generalitat de Catalunya, Girona, Spain. [Laquente-Sáez B] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. Universitat de Barcelona, Barcelona, Spain. Hospital del Mar, Parc de Salut Mar, Generalitat de Catalunya, Barcelona, Spain. [Layos-Romero L] Servei de Farmàcia, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Lezcano-Rubio C] Servei d’Oncologia Radioteràpica, Institut Català d’Oncologia (ICO) Badalona, Generalitat de Catalunya, Badalona, Spain. [Macarulla-Mercadé T] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. [Navalpotro-Yagüe B] Servei d’Oncologia Radioteràpica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. Universidad Autónoma de Madrid, Madrid, Spain. [Gilabert-Sotoca M] Servei de Farmàcia, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Verdaguer-Mata H] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. Vall d’Hebron Institut d’Oncologia (VHIO), Generalitat de Catalunya, Barcelona, Spain. Institut Català d’Oncologia (ICO) L’Hospitalet, Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain., and Institut Català de la Salut
- Subjects
Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES] ,Physical Phenomena::Radiation [PHENOMENA AND PROCESSES] ,Pàncrees - Càncer ,Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [DISEASES] ,neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma [ENFERMEDADES] ,Other subheadings::/therapy [Other subheadings] ,fenómenos físicos::radiación [FENÓMENOS Y PROCESOS] ,Adenocarcinoma ,Irradiació - Tractament ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES] ,Otros calificadores::/terapia [Otros calificadores] - Abstract
Tractament mèdic; Tractament amb irradiació; Adenocarcinoma; Pàncrees; Càncer Tratamiento médico; Tratamiento con irradiación; Adenocarcinoma; Páncreas; Cáncer Medical treatment; Irradiation treatment; Adenocarcinoma; Pancreas; Cancer El càncer de pàncrees se situa com la tercera causa més freqüent de càncer en la forma d'adenocarcinoma ductal pancreàtic. És un dels càncers més agressius i amb un percentatge més baix de curació. Els objectius d'aquesta guia són: -Desenvolupar, difondre, implementar i avaluar resultats de la ICO-ICSPraxi de càncer de pàncrees. -Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta institució. -Implementar els resultats de la terapèutica en els pacients amb adenocarcinoma de pàncrees tractats d'acord amb les recomanacions d'aquesta guia.
- Published
- 2018
41. 478P TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
- Author
-
Xavier Sanjuan, M.A. Cañas, P. Fernandez-Calotti, E. Aranda Aguilar, H. Ps, F. Losa, L. Layos Romero, David Páez, R. Salazar, B. Queralt, Carlos Ferreira dos Santos, Krisha Desai, M.E. Elez Fernandez, Patrick Varun Lawrence, Anguraj Sadanandam, Chanthirika Ragulan, D. Azuara, Elisa Fontana, and Adriana Lopez-Doriga
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Internal medicine ,medicine ,Wild type ,Hematology ,medicine.disease ,business - Published
- 2021
- Full Text
- View/download PDF
42. Acetato de eslicarbazepina en neuralgia del trigémino
- Author
-
Álvaro Sánchez-Larsen, Almudena Layos-Romero, Tomás Segura, and D. Sopelana
- Subjects
business.industry ,Medicine ,Neurology (clinical) ,business ,lcsh:Neurology. Diseases of the nervous system ,lcsh:RC346-429 - Published
- 2020
43. Eslicarbazepine acetate for trigeminal neuralgia
- Author
-
D. Sopelana, Tomás Segura, Álvaro Sánchez-Larsen, and Almudena Layos-Romero
- Subjects
medicine.medical_specialty ,business.industry ,Trigeminal Neuralgia ,medicine.disease ,Dermatology ,lcsh:RC346-429 ,Eslicarbazepine acetate ,Trigeminal neuralgia ,Dibenzazepines ,Materials Chemistry ,Medicine ,Humans ,Anticonvulsants ,business ,lcsh:Neurology. Diseases of the nervous system ,medicine.drug - Published
- 2020
44. Additional file 1 of Low-value care practice in headache: a Spanish mixed methods research study
- Author
-
Pozo-Rosich, Patricia, Layos-Romero, Almudena, Martin-Delgado, Jimmy, Pascual, Julio, Bailón, Cristina, Tentor, Ana, Santiago, Alejandro, Ignacio, Emilio, Torrés, Antonio, and Mira, José Joaquín
- Subjects
Data_FILES - Abstract
Additional file 1: Supplemental file 1. Do not Do recommendations proposed by the expert panel.
- Published
- 2020
- Full Text
- View/download PDF
45. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report
- Author
-
Alba Martínez-García, Emilio Ignacio, José Joaquín Mira, Irene Carrillo, Antoni Torres, Cristina Bailón-Santamaría, Patricia Pozo-Rosich, Julio Pascual, Sandra Rodríguez-Justo, Dolores Jiménez-Hernández, Almudena Layos-Romero, Universidad de Cantabria, and Enfermería y Fisioterapia
- Subjects
Consensus ,Health literacy ,Health administration ,quality in health care ,Patient safety ,Patient satisfaction ,Health care ,Humans ,Medicine ,migraine ,business.industry ,Communication ,Headache ,General Medicine ,Emergency department ,medicine.disease ,Neurology ,Migraine ,Patient Satisfaction ,Medical emergency ,Emergency Service, Hospital ,business ,qualitative research ,Qualitative research - Abstract
BackgroundHeadache is one of the most prevalent and disabling conditions. Its optimal management requires a coordinated and comprehensive response by health systems, but there is still a wide variability that compromises the quality and safety of the care process.PurposeTo establish the basis for designing a care pathway for headache patients through identifying key subpathways in the care process and setting out quality and clinical safety standards that contribute to providing comprehensive, adequate and safe healthcare.MethodA qualitative research study based on the consensus conference technique. Eleven professionals from the Spanish National Health System participated, seven of them with clinical experience in headache and four specialists in healthcare management and quality. First, identification of the key subpathways in the care process for headache, barriers/limitations for optimal quality of care, and quality and safety standards applied in each subpathway. Second, two consecutive consensus rounds were carried out to assess the content of the subpathway level descriptors, until the expert agreement was reached. Third, findings were assessed by 17 external healthcare professionals to determine their understanding, adequacy and usefulness.ResultsSeven key subpathways were identified: (1) primary care, (2) emergency department, (3) neurology department, (4) specialised headache unit, (5) hospitalisation, (6) outpatients and (7) governance and management. Sixty-seventh barriers were identified, the most frequent being related to diagnostic errors (36,1%), resource deficiency (25%), treatment errors (19,4%), lack of health literacy (13,9%) and inadequate communications with care transitions (5,6%). Fifty-nine quality and 31 safety standards were defined. They were related to evaluation (23.3%), patient safety (21.1%), comprehensive care (12.2%), treatment (12.2%), clinical practice guidelines (7.8%), counselling (6.7%), training (4.4%) and patient satisfaction (3.3%).ConclusionsThis proposal incorporates a set of indicators and standards, which can be used to define a pathway for headache patients and determine the levels of quality.
- Published
- 2020
46. Neurological Manifestations in Hospitalized Patients with COVID-19: A Retrospective, Observational Study from a Spanish Population. The ALBACOVID Registry
- Author
-
Carlos Manuel Romero-Sánchez, Inmaculada Díaz-Maroto, Eva Fernández-Díaz, Álvaro Sánchez-Larsen, Almudena Layos-Romero, Jorge García-García, Esther González, Inmaculada Redondo-Peñas, Ana Belén Perona-Moratalla, José Antonio Del Valle-Pérez, Julia Gracia-Gil, Laura Rojas-Bartolomé, Inmaculada Feria-Vilar, María Monteagudo, María Palao, Elena Palazón-García, Cristian Alcahut-Rodríguez, David Sopelana-Garay, Yóscar Moreno, Javaad Ahmad, and Tomás Segura
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Pediatrics ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Hospitalized patients ,Retrospective cohort study ,medicine.disease_cause ,Spanish population ,Epidemiology ,Medicine ,High incidence ,business ,Coronavirus - Abstract
Background: The coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019 Spain is one of the most affected countries, with high incidence a
- Published
- 2020
- Full Text
- View/download PDF
47. Proposal of a clinical care pathway for quality and safe management of headache patients : a consensus study report
- Author
-
Pascual Gómez, Julio, Pozo-Rosich, Patricia, Carrillo, Irene, Rodríguez-Justo, Sandra, Jiménez-Hernández, Dolores, Layos-Romero, Almudena, Bailón-Santamaría, Cristina, Torres, Antonio, Martínez-García, Alba, Ignacio, Emilio, Mira, José Joaquín, Pascual Gómez, Julio, Pozo-Rosich, Patricia, Carrillo, Irene, Rodríguez-Justo, Sandra, Jiménez-Hernández, Dolores, Layos-Romero, Almudena, Bailón-Santamaría, Cristina, Torres, Antonio, Martínez-García, Alba, Ignacio, Emilio, and Mira, José Joaquín
- Abstract
Headache is one of the most prevalent and disabling conditions. Its optimal management requires a coordinated and comprehensive response by health systems, but there is still a wide variability that compromises the quality and safety of the care process. To establish the basis for designing a care pathway for headache patients through identifying key subpathways in the care process and setting out quality and clinical safety standards that contribute to providing comprehensive, adequate and safe healthcare. A qualitative research study based on the consensus conference technique. Eleven professionals from the Spanish National Health System participated, seven of them with clinical experience in headache and four specialists in healthcare management and quality. First, identification of the key subpathways in the care process for headache, barriers/limitations for optimal quality of care, and quality and safety standards applied in each subpathway. Second, two consecutive consensus rounds were carried out to assess the content of the subpathway level descriptors, until the expert agreement was reached. Third, findings were assessed by 17 external healthcare professionals to determine their understanding, adequacy and usefulness. Seven key subpathways were identified: (1) primary care, (2) emergency department, (3) neurology department, (4) specialised headache unit, (5) hospitalisation, (6) outpatients and (7) governance and management. Sixty-seventh barriers were identified, the most frequent being related to diagnostic errors (36,1%), resource deficiency (25%), treatment errors (19,4%), lack of health literacy (13,9%) and inadequate communications with care transitions (5,6%). Fifty-nine quality and 31 safety standards were defined. They were related to evaluation (23.3%), patient safety (21.1%), comprehensive care (12.2%), treatment (12.2%), clinical practice guidelines (7.8%), counselling (6.7%), training (4.4%) and patient satisfaction (3.3%). This proposal inco
- Published
- 2020
48. Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report
- Author
-
Universidad de Sevilla. Departamento de Medicina, Pascual, Julio, Pozo-Rosich, P., Carrillo,Irene, Rodríguez-Justo, Sandra, Jiménez Hernández, María Dolores, Layos-Romero, Almudena, Bailón-Santamaría, Cristina, Martínez- García, Alba, Ignacio, Emilio, Mira, José Joaquín, Universidad de Sevilla. Departamento de Medicina, Pascual, Julio, Pozo-Rosich, P., Carrillo,Irene, Rodríguez-Justo, Sandra, Jiménez Hernández, María Dolores, Layos-Romero, Almudena, Bailón-Santamaría, Cristina, Martínez- García, Alba, Ignacio, Emilio, and Mira, José Joaquín
- Abstract
Background Headache is one of the most prevalent and disabling conditions. Its optimal management requires a coordinated and comprehensive response by health systems, but there is still a wide variability that compromises the quality and safety of the care process. Purpose To establish the basis for designing a care pathway for headache patients through identifying key subpathways in the care process and setting out quality and clinical safety standards that contribute to providing comprehensive, adequate and safe healthcare. Method A qualitative research study based on the consensus conference technique. Eleven professionals from the Spanish National Health System participated, seven of them with clinical experience in headache and four specialists in healthcare management and quality. First, identification of the key subpathways in the care process for headache, barriers/limitations for optimal quality of care, and quality and safety standards applied in each subpathway. Second, two consecutive consensus rounds were carried out to assess the content of the subpathway level descriptors, until the expert agreement was reached. Third, findings were assessed by 17 external healthcare professionals to determine their understanding, adequacy and usefulness. Results Seven key subpathways were identified: (1) primary care, (2) emergency department, (3) neurology department, (4) specialised headache unit, (5) hospitalisation, (6) outpatients and (7) governance and management. Sixty-seventh barriers were identified, the most frequent being related to diagnostic errors (36,1%), resource deficiency (25%), treatment errors (19,4%), lack of health literacy (13,9%) and inadequate communications with care transitions (5,6%). Fifty-nine quality and 31 safety standards were defined. They were related to evaluation (23.3%), patient safety (21.1%), comprehensive care (12.2%), treatment (12.2%), clinical practice guidelines (7.8%), counselling (6.7%), training (4.4%) and patient satis
- Published
- 2020
49. Discinesias paroxísticas tras cobaltoterapia
- Author
-
Amanda Álvarez Noval and Almudena Layos Romero
- Published
- 2021
- Full Text
- View/download PDF
50. P-318 Survival outcomes among patients with locally advanced gastric cancer treated within a multidisciplinary gastro-esophageal cancer functional unit
- Author
-
A. Ferrando Díez, A. Plaja Salarich, C. Hierro Carbó, E. Garsot Savall, M. Caro Gallarín, A. Clavell Font, L. Layos Romero, S. España Fernández, O. García Calduch, R. Rodríguez Iniesta, J. Colan Hernández, R. López Martos, A. Calsina Berna, M. Sendrós Madroño, M. Sendra Gonzalez, M. Riquelme Olivares, A. Hernandez Marfil, M. López Cuellar, M. José Osuna, A. Font Pous, J. Manzano Mozo, and C. Bugés Sánchez
- Subjects
Oncology ,Hematology - Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.